SECOND AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • February 16th, 2016 • Immune Design Corp. • Pharmaceutical preparations • Washington
This Second Amended and Restated License Agreement (this “Agreement”) is made as of December 23, 2015 (the “Second Restated Effective Date”), by and between the Infectious Disease Research Institute, a Washington not-for-profit corporation having a place of business at 1616 Eastlake Ave. E., Suite 400, Seattle, WA 98102 (“IDRI”), and Immune Design Corp., a Delaware corporation having a place of business at 1616 Eastlake Ave. E., Suite 310, Seattle, WA 98102 (“Immune Design”). IDRI and Immune Design are herein referred to individually as a “Party” and collectively as the “Parties.”
